secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2026-08-07T20:06:19+00:00
Accession:  0001104659-26-092691
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents Q2 2026 presentation omits financials; targets H2 2026 break-even
------------------------------------------------------------------------------

- Targets operating cash-flow break-even in H2 2026 via strategic workforce and cost reduction plan.
- Restructuring direct sales team and strategy in Germany; cites war in Iran as a risk factor.
- Seeks FDA and Health Canada regulatory approval; must comply with existing debt covenants.
- Q2 2026 earnings presentation dated Aug 6, 2026; no specific revenue or EPS figures in furnished exhibit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465926092691/0001104659-26-092691-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465926092691/tm2622604d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-092691

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer